—
C+
C+ The full Closelook — membership. Open the C+ overview

Crispr Therapeutics AG (CRSP) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Crispr Therapeutics AG

CRSP in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Crispr Therapeutics builds gene-editing medicines around its CRISPR/Cas9 platform, altering specific DNA sequences to treat serious diseases. Its lead product, Casgevy, edits a patient's own stem cells to treat sickle cell disease and beta-thalassemia, developed with partner Vertex Pharmaceuticals. The pipeline extends into CAR T cell therapies for cancer and autoimmune disease, in-vivo editing for cardiovascular targets, and a stem-cell approach to type 1 diabetes. It is headquartered in Zug, Switzerland.
Where it sits in the stack
Crispr Therapeutics carries no seat in our index and sits outside the AI build-out stack entirely; it belongs to our healthcare universe, in the biotechnology sleeve, as a gene-editing developer rather than an infrastructure or compute name.
Who it is priced against
Closelook has not set a peer group for this name; the comparison the market draws most often is with Intellia Therapeutics, another CRISPR-based drug developer.
Why Closelook tracks it
It holds no index seat and carries no Closelook score. Its only diary mentions come from strategy and heresy pieces citing the CRSP database behind Bessembinder's stock-return study, a reference to the academic dataset rather than coverage of the company itself.
What the diary watches
The diary watches how the Vertex partnership evolves and whether Casgevy's uptake and the wider pipeline's clinical progress eventually earn the name its own index seat and score.

Crispr Therapeutics AG (CRSP) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for CRSP, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Crispr Therapeutics AG (CRSP)?

Crispr Therapeutics AG trades as CRSP on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-18.

Is CRSP in a Closelook index?

Not currently — Crispr Therapeutics AG is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does CRSP trade against its moving averages?

Recovery attempt under the 200-day: Trades +8.1% vs the 50-day and +7.6% vs the 200-day average, 27% below the 52-week high and +29.9% off the 52-week low; a death cross printed 3 sessions ago. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Crispr Therapeutics AG do?

Crispr Therapeutics builds gene-editing medicines around its CRISPR/Cas9 platform, altering specific DNA sequences to treat serious diseases. Its lead product, Casgevy, edits a patient's own stem cells to treat sickle cell disease and beta-thalassemia, developed with partner Vertex Pharmaceuticals. The pipeline extends into CAR T cell therapies for cancer and autoimmune disease, in-vivo editing for cardiovascular targets, and a stem-cell approach to type 1 diabetes. Closelook has not set a peer group for this name; the comparison the market draws most often is with Intellia Therapeutics, another CRISPR-based drug developer.

Where does Crispr Therapeutics AG sit in the AI build-out?

Crispr Therapeutics carries no seat in our index and sits outside the AI build-out stack entirely; it belongs to our healthcare universe, in the biotechnology sleeve, as a gene-editing developer rather than an infrastructure or compute name. It holds no index seat and carries no Closelook score. Its only diary mentions come from strategy and heresy pieces citing the CRSP database behind Bessembinder's stock-return study, a reference to the academic dataset rather than coverage of the company itself.

Where has Closelook written about Crispr Therapeutics AG?

Crispr Therapeutics AG appears in 2 Closelook pieces, most recently Strategy: Portfolio Construction — The Barbell Architecture, Why the Middle Is Decay (2026-05-23); Heresy: US Equities — Don’t Buy U.S. Stocks · Closelook Heresy (2026-05-08). What Closelook said most recently: Bessembinder's 2018 paper showed that, of the US common stocks in the CRSP database from 1926 to 2016, the best-performing 4% accounted for the entire net wealth ever created — the other 96% collectively matched one-month Treasury bills. (Strategy, 2026-05-23). The "Mentioned on Closelook" block on this page lists the long reads, the reference entries and the dailies that name it.

What does this page show?

A live price chart with SMA overlays and drawing tools for CRSP, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Mentioned on Closelook 2 pieces · newest: Strategy, “Portfolio Construction — The Barbell Architecture, Why the Middle Is Decay” (2026-05-23)

Mentioned on Closelook

Where CRSP appears in the diary — 2 pieces, newest first. Every link is our own writing.

Long reads

Related in the Closelook universe